Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 5205-5210

  Gotoh, Takahiro ^a   Hosoi, Hajime ^a   Iehara, Tomoko ^a   Kuwahara, Yasumichi ^a   Osone, Shinya ^a   Tsuchiya, Kunihiko ^a   Ohira, Miki ^a   Nakagawara, Akira ^a   Kuroda, Hiroshi ^a   Sugimoto, Tohru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ADOLESCENT; ARTICLE; CANCER REGRESSION; CANCER STAGING; CHILD; DIAGNOSTIC ACCURACY; GENE AMPLIFICATION; HUMAN; INFANT; LEUKOCYTE; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SOUTHERN BLOTTING; DIFFERENTIAL DIAGNOSIS; EVALUATION; FEMALE; GENETICS; MALE; NEWBORN; POLYMERASE CHAIN REACTION; PREDICTION AND FORECASTING; PRESCHOOL CHILD; PROGNOSIS;

ADOLESCENT; BLOTTING, SOUTHERN; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 24644434435     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.014     Document Type: Article

References (25)

1. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984
2. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
3. Brodeur GM, Maris JM, Yamashiro DJ, et al: Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 19:93-101, 1997
4. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11:1466-1477, 1993
5. Castleberry RP, Prichard J, Ambros P, et al: The International Neuroblastoma Risk Groups (INRG): A preliminary report. Eur J Cancer 33: 2113-2116, 1997
6. Shimada H, Ambros IM, Dehner LP, et al: The International Neuroblastoma Pathology Classification System (the Shimada system). Cancer 86:364-372, 1999
7. Shapiro B, Chakrabarty M, Cohn EM, et al: Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51:2116-2120, 1983
8. Sozzi G, Conte D, Leon M, et al: Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902-3908, 2003
9. Sozzi G, Musso K, Ratcliffe C, et al: Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: A prospect for early diagnosis. Clin Cancer Res 5:2689-2692, 1999
10. Chen X, Bonnefoi H, Diebold-Berger S, et al: Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 5:2297-2303, 1999
11. Silva JM, Dominguez G, Garcia JM, et al: Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations. Cancer Res 59:3251-3256, 1999
12. Combaret V, Audoynaud C, Iacono I, et al: Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res 62:3646-3648, 2002
13. Akiyama K, Kanda N, Yamada M, et al: Megabase-scale analysis of the origin of N-myc amplicons in human neuroblastoma. Nucleic Acids Res 22:187-193, 1994
14. Gotoh T, Sugihara H, Matsumura T, et al: Human neuroblastoma demonstrating clonal evolution in vivo. Genes Chromosomes Cancer 22:42-49, 1998
15. Spitz R, Hero B, Skowron M, et al: MYCN-status in neuroblastoma: Characteristics of tumours showing amplification, gain, and non-amplification. Eur J Cancer 40:2753-2759, 2004
16. Gelmini S, Orlando C, Sestini R, et al: Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification. Clin Chem 43:752-758, 1997
17. Claudia CR, Maria LB, Gian PT, et al: Real-time quantitative PCR for the measurement of MYCN amplification in human neuroblastoma with the TaqMan detection system. Clin Chem 45:1918-1924, 1999
18. Chiang PW, Beer DG, Wei WL, et al: Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res 5:1381-1386, 1999
19. Hann HWL, Evans AE, Siegel SE, et al: Prognostic importance of serum ferritin in patients with stage III and IV neuroblastoma: The Children's Cancer Study Group experience. Cancer Res 45:2843-2848, 1985
20. Quinn JJ, Altman AJ, Frantz CN, et al: Serum lactic dehydrogenase, an indicator of tumor activity in neuroblastoma. J Pediatr 97:89-91, 1980
21. Massaron S, Seregni E, Luksch R, et al: Neuron-specific enolase evaluation in patients neuroblastoma. Tumour Biol 19:261-268, 1998
22. Ikematsu S, Nakagawara A, Nakamura Y, et al: Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br J Cancer 88:1522-1526, 2003
23. Sozzi G, Conte D, Mariani L, et al: Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 61:4675-4678, 2001
24. Bunn PA: Early detection of lung cancer using serum RNA or DNA markers: Ready for "prime time" or for validation? J Clin Oncol 21:3891-3893, 2003
25. Swinkels DW, Wiegerinck E, Steegers EAP, et al: Effect of blood-processing protocols on cell-free DNA quantification in plasma. Clin Chem 49:525-526, 2003